Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | S100A4 | P26447 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.53 |
| ▸ | METAP1 | P53582 | 1/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2601324 | 0.90 | METAP1 (0.60) | CES1S100A4METAP1SRD5A1SRD5A2 | |
| SCHEMBL6387824 | 0.89 | L3MBTL1 (0.64) | CES1MAOBTDP1L3MBTL1S100A4 | |
| SCHEMBL4068688 | 0.88 | SRD5A1 (0.55) | CES1MAOBS100A4SRD5A1SRD5A2 | |
| SCHEMBL10694841 | 0.85 | MAOA (0.67) | CES1TDP1L3MBTL1S100A4MAPK14 | |
| SCHEMBL29408351 | 0.82 | CES1 (0.90) | CES1MAOBTDP1L3MBTL1MAPK14 | |
| SCHEMBL44496 | 0.82 | CES1 (0.90) | CES1MAOBTDP1L3MBTL1MAPK14 | |
| SCHEMBL29437756 | 0.82 | CES1 (0.90) | CES1MAOBTDP1L3MBTL1MAPK14 | |
| SCHEMBL29669379 | 0.81 | CES1 (0.61) | CES1MAOBTDP1L3MBTL1MAPK14 | |
| SCHEMBL4040669 | 0.81 | CES1 (0.61) | CES1MAOBTDP1L3MBTL1MAPK14 | |
| SCHEMBL2312578 | 0.81 | AKR1B1 (0.58) | MAOBMAPK14METAP1MAOASRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210186969-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | Janssen Biopharma, Inc. (US) | 2021-06-24 | — | — | US | disclosed |
| US-10980805-B2 | Aza-pyridone compounds and uses thereof | Janssen Biopharma, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3778603-A1 | 7,8-DIHYDRO-3H-PYRAZINO[1,2-B]PYRIDAZINE-3,5(6H)-DIONE COMPOUNDS AND USES THEREOF | Janssen BioPharma, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3030566-B1 | 7,8-DIHYDRO-3H-PYRAZINO[1,2-B]PYRIDAZINE-3,5(6H)-DIONE COMPOUNDS AND USES THEREOF | JANSSEN BIOPHARMA INC (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10702523-B2 | AZA-pyridone compounds and uses thereof | Janssen Biopharma, Inc. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200030328-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | Janssen Biopharma, Inc. (US) | 2020-01-30 | — | — | US | disclosed |
| US-20190314373-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | ALIOS BIOPHARMA, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-10251882-B2 | Aza-pyridone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20160228438-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | ALIOS BIOPHARMA, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160228438-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | ALIOS BIOPHARMA, INC. | 2016-08-11 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2006-03-23 | — | — | US | disclosed |
| EP-1519915-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004052847-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-4586996-A | Surface hardner for nylon lens | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1986-05-06 | — | — | US | disclosed |
| US-4548933-A | Sedative compositions containing 10-piperazino-5-cyanomethylene-dibenzo[a,d]-cycloheptenes | BASF AKTIENGESELLSCHAFT (DE) | 1985-10-22 | — | — | US | disclosed |
| EP-0035711-B1 | 10-SUBSTITUTED-5-CYANOMETHYLENE-DIBENZO-(A,D)CYCLOHEPTENES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1984-05-09 | — | — | EP | disclosed |
| US-4447610-A | SEDATIVES, TRANQUILIZERS, NEUROLEPTIC AGENTS, MUSCLE RELAXANTS AND ANTIDEPRESSANTS | BASF AKTIENGESELLSCHAFT (DE) | 1984-05-08 | — | — | US | disclosed |
| EP-0035711-A2 | 10-Substituted-5-cyanomethylene-dibenzo-(a,d)cycloheptenes, process for their preparation and pharmaceutical compositions containing them | BASF Aktiengesellschaft (DE) | 1981-09-16 | — | — | EP | disclosed |
| US-4003915-A | ANTICONVULSANTS, PARKINSON*S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030328-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | PNPO, ITPA, PDXK | CES1 3213/4885MAOB 145/4885TDP1 965/4885 |
| US-10980805-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | CES1 3213/4885MAOB 145/4885TDP1 965/4885 |
| US-20190314373-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | PNPO, ITPA, PDXK | CES1 3213/4885MAOB 145/4885TDP1 965/4885 |
| US-10251882-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | CES1 3213/4885MAOB 145/4885TDP1 965/4885 |
| US-20210186969-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | PNPO, ITPA, PDXK | CES1 3213/4885MAOB 145/4885TDP1 965/4885 |
| US-10702523-B2 | AZA-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | CES1 3213/4885MAOB 145/4885TDP1 965/4885 |
| US-20160228438-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | PNPO, ITPA, PDXK | CES1 3213/4885MAOB 145/4885TDP1 965/4885 |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | NR5A1, NR3C2, NR3C1 | CES1 435/4885MAOB 2012/4885TDP1 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.